Skip to content

Impact of Training on Gait and Strength in Stroke Survivors

Gait Performance and Lower-limb Muscle Strength Improved in Both Upper-limb and Lower-limb Isokinetic Training Programs in Individuals With Chronic Stroke

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01818349
Enrollment
30
Registered
2013-03-26
Start date
2002-03-31
Completion date
2007-12-31
Last updated
2013-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, exercise, muscle strength, gait, rehabilitation

Brief summary

Background: A discrepancy between strength gain and gait changes following various training programs aimed at improving gait function after stroke has been noted. A mismatch between the training program and gait parameters could explain this finding. Objective: To evaluate the impact of an isokinetic-strengthening program, matching the requirements of the affected lower-limb muscle groups involved in the energy generation of gait, to a control intervention, on gait performance and muscle strength. Hypothesis: The isokinetic training program of the affected lower-limb muscles would produce greater changes in gait performance and strength than a control intervention not aiming at training these muscle groups. Design: Single-blinded randomized controlled trial. Participants: A convenient sample of 30 individuals with chronic hemiparesis. Interventions: Participants were randomly assigned into two groups (n=15), each training three times/week for six weeks. The experimental group trained the affected plantarflexors, hip flexors and extensors concentrically, while the control group trained the affected upper-limb muscles. Main outcome measures: Baseline values and post-training values, taken at the end of the training program, of maximal voluntary concentric strength, gait speed and peak positive power.

Interventions

OTHERisokinetic lower-limb training

concentric training of the affected plantarflexors, hip flexors and hip extensors

OTHERisokinetic upper-limb training

concentric training of the affected wrist extensors, elbow flexors and shoulder flexors

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Université de Montréal
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* have a chronic (six months or more) unilateral stroke * be able to walk 10 meters independently with or without a cane * present residual weakness at the affected lower limb * have an activity tolerance of at least two hours with a rest period

Exclusion criteria

* receptive aphasia * incontinence * unstable medical condition * history of injury * anesthesia at the lower limbs

Design outcomes

Primary

MeasureTime frameDescription
change in gait speedgait speed was assessed at baseline and at the completion of the 6-week training (i.e. week #7)change in gait speed, in meter/second, was assessed as the difference between the baseline and week #7 values.
change in peak positive powerpeak positive power was assessed at baseline and at the completion of the 6-week training (i.e. week #7)peak positive power was evaluated at the affected plantarflexors, hip flexors and hip extensors. Also, change in peak positive power, in weight/kilogram, was assessed as the difference between the baseline and week #7 values.

Secondary

MeasureTime frameDescription
change in maximal voluntary concentric strengthmaximal voluntary concentric strength was assessed at baseline and at the completion of the 6-week training (i.e. week #7)maximal voluntary concentric strength was evaluated at the affected plantarflexors, hip flexors and hip extensors. Also, change in maximal voluntary concentric strength, in Newton-metre, was assessed as the difference between the baseline and week #7 values.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026